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ABSTRACT 
SUBANESTHETIC KETAMINE FOR POSTOPERATIVE ANALGESIA:  
AN EVIDENCED-BASED PROJECT 
by Jeremy Alan Vance 
December 2017 
Roughly 100 million surgical procedures are performed in the United States 
(U.S.) each year and more than 80% of these patients experience acute postoperative 
pain.  Pain costs the U.S. an estimated $560 to $635 billion annually and is a significant 
contributor to national rates of mortality, morbidity, and disability.  Despite these 
findings, patients continue to receive suboptimal postoperative pain relief.   
The adjunct administration of subanesthetic ketamine is opioid-sparing and can 
improve the effectiveness of a multimodal pain management approach.  This project used 
an exploratory descriptive design to examine how an evidence-based presentation 
impacted the clinical practice of certified registered nurse anesthetists (CRNAs).  A 
questionnaire describing individual pain management practices before and after an 
evidence-based presentation on multimodal pain management using subanesthetic 
ketamine was included.  Participants completed a pre-intervention questionnaire.  The 
student registered nurse anesthetist (SRNA) then presented an evidence-based teaching 
intervention on subanesthetic ketamine based on a synthesis of current research.  
Consistent with current literature, a subanesthetic ketamine dose of 0.5 mg/kg was 
suggested to participants.  As recommended in the literature, subanesthetic ketamine 
could be administered during the preoperative or intraoperative periods with effective 
control of pain on emergence.  Two weeks later, a post-intervention questionnaire was 
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mailed to the SRNA using provided self-addressed envelopes.  All four participants 
reported the evidence-based intervention influenced their consideration of subanesthetic 
ketamine administration.  Increases in subanesthetic administration frequencies were also 
noted. 
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CHAPTER I – INTRODUCTION 
Postoperative pain is a significant concern for surgical patients in the United 
States (U.S.) (Ladha, Patorno, Huybrechts, Liu, Rathmell, & Bateman, 2016).  Most 
patients undergoing a surgical procedure experience acute postoperative pain and less 
than half of these patients report adequate postoperative pain relief (Chou et al., 2016).  
Perioperative pain management is a crucial component of anesthetic care and can affect 
the amount of pain patients feel postoperatively.  Optimal management of this pain poses 
unique challenges to anesthesia providers, as it requires an understanding of the 
pathophysiology of pain, the techniques available to decrease pain, procedure specificity, 
and the situational awareness to assess and direct care as needed.  Inadequate treatment of 
this pain has major consequences to the patient, including needless suffering, delayed 
recovery, and extended hospital stays following surgery.  It also increases the risk for 
developing chronic pain, leads to higher rates of complications, higher morbidity, and 
mortality rates, and places a financial burden on health care recipients in the U.S. (Khana 
et al., 2011). 
Problem Statement 
Roughly 100 million surgical procedures are performed in the U.S. each year 
(Centers for Disease Control and Prevention [CDC], 2010). Approximately 86% of 
patients undergoing a surgical procedure in the U.S. experience acute postoperative pain 
and 75% of these patients report the severity as moderate, severe, or extreme 
(Apfelbaum, Chen, Mehta, & Gan, 2003; Chou et al., 2016).  Pain costs the U.S. an 
estimated $560 to $635 billion dollars annually and is a significant contributor to national 
rates of mortality, morbidity, and disability (Institute of Medicine [IOM], 2011).  
 2 
Approximately $261 to $300 billion per year are spent on medical care associated with 
pain (Gaskin & Richard, 2011).  This estimate does not include indirect costs of pain, 
e.g., missed working days and lost wages.  The Institute of Medicine (IOM) provides 
three estimates of indirect costs in the U.S. per year: missed working days at about $11.6 
to $12.7 billion, missed hours of work at about $95.2 to $96.5 billion, and lower wages at 
about $190.6 to $226.3 billion (IOM, 2011).  Inadequate treatment of postoperative pain 
results in higher utilization of resources and increased hospitalization and pharmaceutical 
costs (Strassels, Connie, & Daniel, 2002). 
Poorly managed postoperative pain is associated with adverse clinical outcomes 
(Gan, Habib, Miller, White, & Apfelbaum, 2014).  Some of these outcomes include 
thromboembolisms, coronary ischemia, pulmonary complications, longer hospital stays, 
higher readmission rates, needless suffering, increased risk of post-surgical 
complications, and development of chronic pain (American Society of Anesthesiologists 
[ASA], 2012; Apfelbaum et al., 2003).  Unrelieved postoperative pain is also associated 
with increased morbidity and mortality rates, and increased hospital costs (Apfelbaum et 
al., 2003).  Gan, Habib, Miller, White, and Apfelbaum (2014) examined the preoperative 
psychological stresses associated with surgery and found that post-surgical pain was the 
primary concern of 80% of patients.  Of these patients, roughly 53% reported high levels 
of anxiety (Gan et al., 2014).  Anxiety is associated with increased heart rate and blood 
pressure, arrhythmias, shortness of breath, and sleep problems.  Anxiety can make pain 
worse; it enhances the pain experience and decreases a patient’s coping ability (Institute 
for Quality and Efficiency in Health Care, 2014). 
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Background and Significance 
In 1996, The American Pain Society (APS) reported that pain should be addressed 
with the same regard as other vital signs.  They emphasized the importance of routine and 
continual assessments with necessary interventions to treat pain (American Pain Society 
[APS], 2008).  In 2000, The Joint Commission introduced an initiative stressing that 
patients have the right to appropriate assessment and management of pain, further 
emphasizing the importance of pain as the fifth vital sign.  Over the last two decades, 
concerted efforts by federal and private agencies have focused on improving pain 
treatment and setting pain management standards (APS, 2008). Collectively, these 
organizations emphasized the need for change in the treatment and prevention of pain. 
Critical developments in pain treatment standards further evolved in 2000 with 
the U.S. Congress’ proclamation of the “Decade of Pain Control and Research” 
(Brennan, 2015, p. 212).  During this time, a dissemination of science, technology, 
research, and evidence-based practice (EBP) began changing pain management practices 
(Brennan, 2015). In 2001, the Joint Commission declared pain management is the 
responsibility of health care providers and consequently established provider standards 
for assessing and managing pain.  The Centers for Medicare and Medicaid (CMS) 
partnered with the Agency for Healthcare Research and Quality (AHRQ) in the early 
2000s to develop the Hospital Consumer Assessment of Healthcare Providers and 
Systems (HCAHPS) (CMS, 2016).  Implemented in 2006, this survey was the first 
publicly reported, nationally standardized survey that measured and compared patients’ 
perceptions of the care they received while in the hospital.  For institutions receiving 
inpatient prospective payment systems (IPPS), a pay-for-performance culture was created 
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and pain management methods now had direct implications on hospital reimbursements, 
creating an economic motivation to improve pain management practices (CMS, 2016).  
Despite these efforts for the last two decades, patients continued to report moderate to 
severe pain after surgery (Apfelbaum et al., 2003; Gan et al., 2014).  
The growing emphasis of adequate pain control and postoperative pain relief 
introduced the concept of multimodal analgesia in the 1990s (Kehlet & Dahl, 1993).  
Multimodal analgesia is the combination of two or more drug classes, or non-
pharmacologic interventions, used to achieve an additive or synergistic reduction in pain 
through complementary mechanisms of action along multiple sites of the nociceptive 
pathway (Helander et al., 2017).  Traditionally, the mainstay of postoperative pain relief 
has been opioids (Ladha et al., 2016).  However, large doses of opioids have undesirable 
side effects such as respiratory depression, sedation, hypotension, nausea, vomiting, and 
constipation (Ladha et al., 2016).  Large doses can also result in acute tolerance, 
hyperalgesia, and central sensitization (ASA, 2012).  In 2012, the APS collaborated with 
the American Society of Anesthesiologists (ASA) and the American Society of Regional 
Anesthesia and Pain Medicine (ASRA) to release a guideline for perioperative pain 
management, strongly recommending the adoption of advanced multimodal analgesia 
protocols for all surgical patients (Chou et al., 2016).  There are numerous treatment 
adjuncts available to implement a multimodal approach including gabapentinoids, 
acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), regional anesthesia, 
and ketamine.  Combing two or more drug classes with different mechanisms of action, 
multimodal analgesia targets specific areas in multiple pain pathways, thus inhibiting 
patients’ sensations and/or perceptions of pain (ASA, 2012; IOM, 2011). 
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Postoperative pain is a serious problem and concern for both anesthesia providers 
and patients.  Despite its inception nearly 40 years ago, ketamine’s resurgence as an 
analgesic is attributed to the low- or subanesthetic dose ranges (Ramachandran & Rewari, 
2016; Yang & Moitra, 2013).  The use of ketamine has been shown to decrease 
perioperative opioid requirements and reduce postoperative pain intensity (Hurley, 
Murphy, & WU, 2015).  Notwithstanding this evidence, some anesthesia providers are 
hesitant to use this drug as a treatment for pain due to various side effects such as 
hallucinations, tachycardia, lacrimation, delirium, psychomimetic effects, or an increase 
in intracranial pressure (Yang & Moitra, 2013).  Recent reports note that ketamine 
administered in lower doses may not produce such side effects; and, subanesthetic 
ketamine was associated with reduced perioperative pain scores, decreased perioperative 
opioid requirements, and reduced postoperative nausea and vomiting (Yang & Moitra, 
2013). 
Research suggests that inadequate analgesia throughout the perioperative period is 
associated with poor health outcomes and significantly contributes to healthcare costs in 
the U.S.  Despite these findings, patients continue to report moderate to severe pain levels 
postoperatively for the last decade (Apfelbaum et al., 2003; Gan et al., 2014).  Therefore, 
the challenge to anesthesia providers is delivering a patient specific plan of care tailored 
to meet the emotional, behavioral, and pharmacological needs of the individual. 
Needs Assessment 
Despite advancements in pharmacology and surgical techniques, more than 80% 
of patients who undergo surgical procedures experience acute postoperative pain (Gan et 
al., 2014).  Early in a clinical rotation, I observed many postoperative patients needing 
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hydromorphone immediately upon arriving to post-anesthesia care unit (PACU).  When I 
asked providers whether they considered administering subanesthetic ketamine as an 
analgesic adjunct, many of them admitted they had not.  Over time, I assessed that 
patients who received intraoperative subanesthetic ketamine had smoother wake-ups and 
did not require an immediate dosing of analgesic upon arrival to PACU.  I considered this 
as opportunity to change CRNAs’ practice to include subanesthetic ketamine to reduce 
the opioid requirements of patients throughout the perioperative period. 
Clinical Question 
Implementing EBP optimizes patient outcomes, lowers healthcare costs, and 
improves quality of care (Melnyk, Fineout-Overholt, Gallagher-Ford, & Kaplan, 2012). 
To identify the best evidence on subanesthetic ketamine, the EBP process began with the 
formulation of a clinical question.  The clinical question for this project was: are CRNAs 
willing to change their current practice to include subanesthetic ketamine as an adjunct in 
the multimodal management of acute postoperative pain? 
Purpose Statement 
The purpose of this project was to evaluate whether CRNAs were willing to 
change their practice to include subanesthetic ketamine as an adjunct in the multimodal 
management of acute postoperative pain.  Evidence suggests that a multimodal approach 
that includes subanesthetic ketamine reduces total opioid consumption during the 
postoperative period and is an effective adjunct for postoperative analgesia (Helander et 
al., 2017).  
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Theoretical Framework 
Model for Evidenced-based Change in Practice 
The EBP movement represented a major paradigm shift in healthcare that is 
driven by research utilization and clinical expertise to inform clinical decision making 
and guide clinical practice (Stevens, 2013).  Evaluating, integrating, and implementing 
EBP in the clinical setting improves patient outcomes, reduces healthcare costs, and 
enhances clinical judgment (Melnyk, Fineout-Overholt, Gallagher-Ford, & Kaplan, 
2012).  Numerous theoretical frameworks, i.e., conceptual models, were developed to 
organize the processes of making an evidence-based change in practice.  
The EBP model by Rosswurm and Larrabee (1999) provided the theoretical 
framework that guided this Doctor of Nursing Practice (DNP) project.  This model was 
designed to systematically guide practice change projects through the process of 
integrating evidence-based changes in practice (Melnyk & Fineout-Overholt, 2011).  The 
model is a progression through six steps from needs assessment through sustaining a 
practice change.  This project used steps one through five.  Step six, sustaining a practice 
change, is discussed in the recommendation section of this paper. 
Step one included identification of a problem and assessment of the need for a 
change in practice that improves acute pain in the postoperative period. The needs 
assessment was based on clinical observation regarding the use of ketamine in a 
multimodal pain management plan and a systematic review of the literature.  Also, 
stakeholders were identified as CRNAs, the student registered nurse anesthetists (SRNA), 
and head of anesthesia at the chosen facility. 
 8 
Step two involved identifying sources of evidence, planning a search, and 
conducting the search for the best evidence on the perioperative use of subanesthetic 
ketamine for acute postoperative pain.  Systematic reviews on subanesthetic ketamine, 
clinical practice guidelines by the APS and the ASA, and single randomized controlled 
trials, were all considered in step two. 
Step three was a critical appraisal and synthesis of the evidence on subanesthetic 
ketamine as an analgesic adjunct for acute postoperative pain.  There was sufficient 
quality evidence supporting the efficacy of subanesthetic ketamine for perioperative pain 
management. A facility in the Southeastern U.S. was considered, as well as, the costs, 
time obligations, and overall feasibility of completing this DNP project in its entirety was 
considered. 
Step four involved defining and designing the proposed practice change that 
included an evidenced based administration plan for subanesthetic ketamine.  This plan 
and administration regimen was presented to the facility’s CRNAs.  Step five involved 
implementing and evaluating this project.  During this time, close communication with 
the participating CRNAs was imperative.  Obtaining verbal feedback from the CRNAs 
regarding implementation of the project and evaluating a need for adjustments to the 
implementation plan of this project was an import aspect in this step.  Evaluating the 
processes as well as the outcomes and costs associated with this project are important for 
making final recommendations for adoption of the practice. 
DNP Essentials 
This project utilized the competencies as outlined in The Essentials of Doctoral 
Education for Advanced Nursing Practice.  Fulfillment of the core essentials of the DNP 
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degree as defined by the American Association of Colleges of Nursing (AACN) are 
necessary to confer the DNP degree (Chism, 2013).  This project employed a systems-
based approach to conceptualize and improve practice quality within the culture and 
structure of the host facility (see Appendix A) (Zaccagnini & White, 2014). 
Review of Literature 
A literature search was conducted in July of 2017 using Ovid (MEDLINE), 
Pubmed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and 
Scopus to identify, appraise, and synthesize current evidence on the use of ketamine in 
acute perioperative pain management (see Figure 1).  Studies meeting inclusion and 
exclusion criteria were identified by title and abstract. Inclusion criteria included: 
systematic reviews, randomized controlled trials (RCTs), and studies published in 
English between 2002 and 2017. Exclusion criteria included: animal or laboratory studies 
and non-English studies. The following search terms were used in various orders and 
combinations: ketamine, postoperative, pain, analgesia, multimodal, low-dose, and 
subanesthetic.  The initial literature search identified 312 studies. Of these, 259 studies 
were duplicates and excluded. A total of 53 articles resulted from this search.  An 
additional 36 articles were excluded according to defined criteria and 17 articles 
remained.  After full text screening data extraction, five studies were appropriate for use 
in this DNP project (see Appendix B). 
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Figure 1. Review of Literature PRISMA Flow Diagram. 
Note: Flow diagram for article selection. Adapted from Moher, D., Liberati A., Tetzlaff J., & Altman, D. (2009). “The PRISMA 
Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.” PLoS Med 6(7): 
e1000097. doi:10.1371/journal.pmed1000097 
 
Ketamine has unique anesthetic properties that make it adaptable to various 
clinical situations.  It is often described as unique because no other single drug has the 
combined hypnotic, analgesic, and amnesic effects that ketamine distinctly shows (Gao, 
Rejaei, & Liu, 2016).  Ketamine is traditionally used as a general anesthetic, especially in 
high risk patients with shock or cardiovascular instability, hypovolemia, trauma, severe 
anemia, and bronchospasm (Nagelhout & Plaus, 2013).  It is also used in obstetrics for 
induction of high risk patients such as those with fetal distress and acute hemorrhage, and 
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ketamine is used to supplement regional techniques during delivery and the postpartum 
period (Nagelhout & Plaus, 2013).  Renewed clinical interest in ketamine has recently led 
to its use in the treatment of depression, suicidal ideations, complex regional pain 
syndromes, cancer pain, alcohol addiction, heroin addiction, asthma exacerbations, 
wheezing, and pain during Propofol injection, (Gao, Rejaei, & Liu, 2016). 
Ketamine is a phencyclidine derivative that predominately effects N-methyl-D-
aspartate (NMDA) receptors via noncompetitive antagonism (Yang & Moitra, 2013).  It 
is primarily supplied as a racemic mixture of the R(-) and S(+) isomer forms (Patel, Patel, 
& Roth, 2011).  The S(+) isomer has 4 times the affinity to bind with NMDA receptors, 
two times the analgesic potency, and fewer psychomimetic effects with its 
administration, than the R(-) isomer.  Ketamine is water and lipid soluble and rapidly 
crosses the blood brain barrier.  Hepatic cytochrome P450 enzymes CYP3A4 and 
CYP2B6 metabolize ketamine into norketamine that is excreted in urine and bile (Patel, 
Patel, & Roth, 2011). 
Ketamine has the unique characteristic of creating dissociation between the 
thalamocortical and limbic systems; in fact, the term referred to as dissociative anesthesia 
was coined specifically for ketamine (Nagelhout & Plaus, 2013).  Unlike other general 
anesthetics, the pharmacokinetic and pharmacodynamic properties of ketamine make it 
an ideal drug for the unstable and high risk patient.  It increases cerebral metabolic rate 
(CMRO2), intracranial pressure (ICP), and cerebral blood volume (CBV).  The 
cardiovascular effects of ketamine occur via sympathetic mediated stimulation and 
inhibition of catecholamine reuptake, producing an increased blood pressure, heart rate, 
and cardiac output.  Ketamine is a potent bronchodilator and enhances thoracic 
 12 
compliance.  Patients maintain airway reflexes, functional residual capacity, minute 
ventilation, and tidal volume.  Ketamine causes nystagmus, increased intraocular pressure 
(IOP), increased oral and respiratory secretions, and increased muscle tone (Kurdi, 
Theerth, & Deva, 2014; Nagelhout & Plaus, 2013). 
Ketamine administration should be carefully considered in patients who are 
comorbid with increased ICP, hypertension (HTN), congestive heart failure (CHF), 
psychiatric disorders, increased IOP, or angina (Kurdi, Theerth, & Deva, 2014).  
However, the pharmacological effects of ketamine are dose dependent.  At lower 
subanesthetic doses, ketamine is primarily an analgesic.  In the subanesthetic dose range, 
there is no respiratory depression and rarely are there psychological and major 
sympathomimetic effects that are observed at general anesthetic dose ranges (Kurdi, 
Theerth, & Deva, 2014; Nagelhout & Plaus, 2013). 
Ketamine’s analgesic properties are attributable to NMDA receptor antagonism 
(White, 2013).  Blocking nociceptive and inflammatory mediators of pain at the NMDA 
receptor decreases a patient’s pain perception. Evidence supports the analgesic properties 
of ketamine; however, many studies cite the heterogeneity of studies and differences in 
dose ranges for low dose ketamine (White, 2013). 
Numerous studies investigate ketamine administration as an analgesic adjunct 
during the perioperative period.  A systematic review by Laskowski, Stirling, McKay, 
and Lim (2011) focused on randomized clinical trials (RCTs) and identified 70 studies 
involving 4,701 patients that used ketamine for perioperative pain control (Laskowski, 
Stirling, McKay, & Lim, 2011).  The study limited ketamine administration without the 
use of regional anesthesia and found that ketamine administration had an opioid sparing 
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effect.  This means that there was a decrease in total opioid consumption and a prolonged 
time to first analgesic administration postoperatively, that was significant for thoracic, 
abdominal, and orthopedic procedures (Laskowski et al., 2011). 
Jouguelet-Lacoste, La Colla, Schilling, and Chelly (2015) examined the use of 
infusion or single, subanesthetic ketamine bolus for postoperative pain control. A 
systematic review of clinical trials and meta-analyses between 1966 and 2013 identified 5 
meta-analyses and 39 clinical trials that met inclusion criteria.  Of the 39 clinical trials on 
subanesthetic ketamine administration, 26 were conducted using a single bolus followed 
by continuous infusion, 11 using only single boluses, and 2 using continuous infusions.  
Out of the 2,482 patients in the 39 clinical trials, 1,403 received ketamine.  The 
distribution of studies according to surgery type were: 7 spine surgeries; 1 cardiac 
surgery; 22 bowel surgeries; 6 arthroplasties; 1 each of ear, nose, and throat surgeries; 
and 2 studies that combined surgeries (Jouguelet-Lacoste et al., 2015). 
All five meta-analyses identified by Jouguelet-Lacoste, et al. concluded that 
subanesthetic ketamine used as an analgesic adjunct decreased pain scores of and opioid 
consumption by surgical patients (Jouguelet-Lacoste et al., 2015). Three of these studies 
reported a mean reduction of morphine consumption of 32% to 50% and a reduction of 
postoperative rescue analgesics of 30% to 50%.  Four out of 5 meta-analyses found that 
pain scores 24 hours postoperatively were significantly reduced in 87.5% of patients who 
received intravenous (iv) ketamine (Jouguelet-Lacoste et al., 2015). To assess 
subanesthetic ketamine, study heterogeneity was noted; however, these studies were 
included in this project based on their primary outcomes, i.e, postoperative opioid 
consumption and/or 24-hour postoperative pain scores (Jouguelet-Lacoste et al., 2015). 
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Six studies, representing 456 patients, 252 of whom received ketamine, assessed 
the use of subanesthetic ketamine as an intraoperative bolus (Jouguelet-Lacoste et al., 
2015).  Four out of 6 studies reported an opioid sparing effect and 2 of the 6 studies 
reported significant reduction in postoperative pain scores.  Subanesthetic ketamine 
administration reduced opioid consumption by an average of 39.25% at 24 hours 
postoperatively.  This study defined subanesthetic ketamine as less than 1.2-mg/kg as an 
infusion and no more than 1-mg/kg when administered as a bolus.  The findings indicate 
that a subanesthetic ketamine infusion at a rate of <1.2-mg/kg/h during the intraoperative 
period decreased opioid consumption by 40% and lowered pain scores.  There were no 
reported complications of subanesthetic ketamine at 48 hours after surgery; however, 
optimal dose or treatment regimen was not ascertained (Jouguelet-Lacoste et al., 2015). 
Kaur, Saroa, and Aggarwal in 2015 identified 80 patients undergoing an open 
cholecystectomy and found subanesthetic ketamine was an effective analgesic up to 6 
hours postoperatively (Kaur, Saroa, & Aggarwal, 2015).  These patients received a pre-
incisional 0.2-mg/kg bolus of ketamine followed by a 0.1-mg/kg/h infusion that ran 
intraoperatively to the end of the procedure.  Pain scores and opioid consumption were 
significantly reduced in the first 6 hours postoperatively.  None of the patients 
experienced ketamine associated side effects such as hallucinations, prolonged sedation, 
or marked dissociation on emergence (Kaur, Saroa, & Aggarwal, 2015). 
Ketamine has a wide margin of safety at subanesthetic and general anesthetic dose 
ranges; and, 4 out of 5 of the meta-analyses identified by Jouguelet-Lacoste et al., 
concluded subanesthetic ketamine was safe when administered as an analgesic adjunct 
and did not increase the incidence of adverse effects (Jouguelet-Lacoste et al., 2015).  
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Subanesthetic ketamine use had no impact on sedation scores and was found to decrease 
the incidence of postoperative nausea and vomiting.  The one study that did report 
negative effects did not deem the effects a safety issue, rather the effects noted in the 
study were psychomimetic in nature, short term, and stopped with the administration of a 
benzodiazepine (Jouguelet-Lacoste et al., 2015). 
Five studies assessed the administration of a single subanesthetic ketamine bolus 
or repeated boluses intraoperatively (Jouguelet-Lacoste et al., 2015).  Subanesthetic 
ketamine was not associated with any serious side effects or any increase in serious side 
effects.  Eleven of the studies reported no difference in subanesthetic ketamine versus 
placebo administration with regards to side effects, i.e., postoperative nausea and 
vomiting, sedation, and psychomimetic effects.  No indications of liver toxicity were 
observed in any of the 39 clinical trials included in this review (Jouguelet-Lacoste et al., 
2015). 
A systematic review by Bell, Dahl, Moore and Kalso (2006) identified 37 
randomized controlled clinical trials and 53 other studies with treatment regimens 
exploring the use of intravenous ketamine for perioperative pain control.  A total of 2,137 
patients were studied, of which 1,210 received ketamine.  Postoperative opioid 
consumption was reduced 24 hours postoperatively with pre-incisional ketamine 
administration in 76% of the treatment groups (Bell, Dahl, Moore and Kalso, 2006).  This 
study reviewed the optimal analgesic doses of ketamine and divided its findings into 4 
groups: 1 group with an estimated dose of 10-mg, 1 group with an estimated dose of 30-
mg, 1 group with an estimated dose of approximately 65-mg, and a final group with an 
estimated dose of approximately 250-270-mg.  The evidence revealed that there was no 
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significant difference in morphine-sparing effects when the ketamine dose was increased 
above a dose of approximately 30mg (Bell et al., 2006). 
The adverse effects of ketamine reported by Bell et al. (2006) were found to be 
equal in the placebo treated groups.  Twenty-one of the 37 trials found no psychomimetic 
effects such as hallucinations, bad dreams, or dysphoria, in the groups receiving 
intravenous ketamine for perioperative pain.  Psychomimetic effects were reported in 
four trials and in one placebo group; however, the study determined these occurrences did 
not impair patient safety.  Four of the trials reported increased sedation scores, 
specifically during the first fifteen minutes postoperatively after extubation.  Diplopia 
was reported as an adverse effect in three of the trials (Bell et al., 2006). 
Summary 
Postoperative pain is undertreated in most surgical patients in the U.S. and has 
been so for over a decade (Chou et al., 2016).  Unrelieved postoperative pain puts 
patients at risks, and, these risks have immediate and potentially chronic consequences.  
This project was guided by Rosswurm and Larrabee (1999) EBP model.  A clinical need 
was identified and a comprehensive literature review appraisal identified the best 
evidence supporting the use of subanesthetic ketamine in a multimodal pain management 
regimen.  Evidence supports the analgesic properties of subanesthetic ketamine 
administration and its efficacy in treating acute perioperative pain.  When added as an 
adjunct to multimodal pain management regimens, subanesthetic ketamine reduced 
postoperative pain scores and opioid requirements postoperatively. 
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CHAPTER II – METHODOLOGY 
Effective postoperative pain management improves clinical and economic 
outcomes (Apfelbaum et al., 2003; Gan et al., 2014).  Despite evidence on the benefits of 
a multimodal perioperative analgesic regimen, a multimodal approach is often underused 
in clinical practice (Benhamou et al., 2008).  This project used an exploratory descriptive 
design to examine how an evidence-based presentation impacted the clinical practice of 
CRNAs. 
Ethical Considerations 
A letter of support from the host facility and an approval from the Institutional 
Review Board (IRB) at The University of Southern Mississippi (USM) was obtained 
(Protocol number 17091103) (see Appendix C and D).  The questionnaires contained the 
following statements: “[p]articipation in this project is voluntary and not required.  
Completion of this survey implies your consent to participate.  You may choose to 
withdraw from this project at any time” (see Appendix E and F).  No personally 
identifiable data was collected. 
Participants 
A convenience sample of CRNAs practicing at a facility located in the 
Southeastern U.S. was recruited.  Recruitment involved the SRNA approaching each of 
the CRNAs and briefly discussing the project, its purpose and goals, and time 
requirements.  Four out of the 5 (80%) CRNAs approached agreed to participate.  The 
fifth CRNA indicated that she was not a full-time employee and declined to participate in 
the project. 
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Design 
This project included a questionnaire describing individual pain management 
practices before and after an evidence-based presentation on multimodal pain 
management using subanesthetic ketamine.  At the start of the project, participants were 
provided with a packet containing a pre-intervention questionnaire with an envelope and 
a post-intervention questionnaire with self-addressed stamped envelope.  Each packet had 
identically numbered pre- and post-intervention questionnaires that were unique to that 
packet.  Using this numbering system preserved anonymity and provided a means of 
evaluating changes in individual participants. 
The SRNA presented an evidence-based teaching intervention on subanesthetic 
ketamine, based on a synthesis of current research.  This presentation provided key points 
on: multimodal pain management, the pharmacokinetics and pharmacodynamics of 
subanesthetic ketamine, the role of subanesthetic ketamine in a multimodal pain 
management regimen, and the clinical applications of subanesthetic ketamine.  Consistent 
with current literature, a subanesthetic ketamine dose of 0.5-mg/kg was suggested to 
participants.  As recommended in the literature, subanesthetic ketamine could be 
administered during the preoperative or intraoperative periods with effective control of 
pain on emergence. 
At the end of the presentation, the participants’ email addresses were collected for 
a post-intervention reminder message that was sent one week.  The email, which was not 
associated with the uniquely numbered pre- and post-intervention questionnaires, 
reminded participants to complete and mail the post-intervention questionnaire.  Two 
weeks after the education intervention, each CRNA completed the post-intervention 
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questionnaire and mailed it to the SRNA in the self-addressed stamped envelope 
provided. 
Data Collection 
The data collection instrument for this DNP project consisted of two seven-item 
Likert type questionnaires (see Appendix E and F).  The pre-intervention questionnaire 
assessed each CRNA’s pre-intervention approach to managing perioperative pain, their 
use of analgesic adjuncts, and their use of subanesthetic ketamine in multimodal 
analgesia.  Participants completed the pre-intervention questionnaire, sealed it in the 
provided blank envelope, and handed the envelope to the SRNA.  The post-intervention 
questionnaire was designed to assess changes in ketamine use by participating CRNAs.  
Each questionnaire took less than 5 minutes to complete.  The SRNA developed the 
questionnaire.  Face validity was achieved through the presentation of the questionnaire 
to subject matter experts. 
Data collected during this project was secured in a locked file cabinet that only 
the SRNA could access.  Electronic data was secured on the SRNA’s password protected 
laptop to which only the SRNA had access.  Six months after the completion of degree 
requirements have been verified, written data will be shredded.  Electronic data will be 
permanently deleted. 
Data Analysis 
Data collected for this project measured individual practice patterns pre- and post-
intervention.  Demographic data limited to gender, age, and number of years in practice, 
was collected.  Frequency counts were used to describe the participants.  Upon 
completion of the project, results were drafted in a final paper for the DNP project.  
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Findings were disseminated to the group of participating CRNAs as well as other  
interested persons at the host organization at which time the project was openly 
discussed. 
Summary 
An exploratory descriptive design was used to examine how an evidenced-
presentation impacted the clinical practice of CRNAs.  CRNAs were recruited and data 
was collected using pre- and post-intervention questionnaires.  The evidenced-based 
presentation was based on a synthesis of current research and served as the intervention 
for this project.  After collection of the post-intervention questionnaires, data was 
analyzed and the results computed. 
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CHAPTER III – RESULTS 
A total of four CRNAs completed the pre- and post-intervention questionnaires 
and engaged in the evidence-based teaching intervention.  Two of the 4 were female 
(50%) and 2 of the 4 were male (50%) (see Figure 2).  The four CRNAs amassed 62 
years of anesthesia experience between them, ranging 6 to 31 years of anesthesia 
experience (see Figure 3). 
 
Figure 2. Demographic Data. 
 
 
GENDER
Male Female
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Figure 3. Years of Anesthesia Experience 
 
When asked if a unimodal or multimodal pain management approach described 
their typical practice, 3 out of 4 (75%) use a multimodal approach and 1 out of 4 (25%) 
use a unimodal approach (see Figure 4).  When asked to rank analgesic adjuncts from 
most to least likely to use, 3 out of 4 (75%) of respondents ranked cyclooxygenase-2 
(COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) as their number one 
or top analgesic adjunct choice.  Three out of 4 (75%) of respondents ranked ketamine as 
their second go to analgesic adjunct.  Calcium channel α-2-δ antagonists, acetaminophen, 
and nonselective NSAIDs, had the third, fourth, and fifth ranking (see Figure 5). 
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Figure 4. Unimodal vs Multimodal Pain Management Regimens. 
 
 
 
Figure 5. Pre- and Post-Intervention Adjunct Rankings.  Adjunct rankings remained 
unchanged pre- and post-intervention. 
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When asked how many times participants administered subanesthetic ketamine in 
the previous two weeks, 2 out of 4 (50%) of participants administered subanesthetic 
ketamine approximately 1 to 2 times, 1 out of 4 (25%) participants administered 
subanesthetic ketamine 3 to 5 times, and 1 out of 4 (25%) did not administer 
subanesthetic ketamine.  Four out of 4 (100%) of the participants completed the pre- and 
post-intervention questionnaires.  Of the participants, 4 out of 4 (100%) stated that the 
evidenced-based intervention influenced their decision to consider the administration of 
subanesthetic ketamine as an adjunct for perioperative pain control.  In the post-
intervention questionnaire, four participants stated he or she used subanesthetic ketamine 
for pain.  Most participants increased their use of subanesthetic ketamine over the two-
week period (see Figure 6). 
 
Figure 6. The Number of Post-Intervention Ketamine Administrations. 
Note: Number of times subanesthetic ketamine was administered over a two-week period, post-intervention. 
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Summary 
This project examined CRNA practice regimens for managing postoperative pain.  
The adjunct use of subanesthetic ketamine in a multimodal pain management plan pre- 
and post-intervention was obtained and described in this section.  Discussion of the 
results including implications and limitations are discussed in the following chapter. 
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CHAPTER IV - Discussion 
Implications for Clinical Practice 
Well-managed postoperative pain is important to anesthesia providers because it 
improves patient outcomes (Gan et al., 2014).  Integrating an opioid-reduced multimodal 
pain management plan that includes subanesthetic ketamine has implications on several 
fronts (see Appendix F).  Opioid related mortalities continue to rise in the U.S. and 
surgical patients receiving opioids are more likely to become opioid dependent and long-
term users (Brummett et al., 2017; Rudd, 2016).  Multimodal pain management plans that 
effectively treat postoperative pain reduces patient opioid consumption, improves patient 
satisfaction, enhances patient recovery, reduces hospital stay, and decreases the 
likelihood of acute pain transitioning to chronic pain (Gan et al., 2014).  Second, 
improving the management of pain reduces healthcare cost in the U.S (Meissner et al., 
2015).  An efficient opioid-reduced anesthetic that incorporates multimodal pain 
management strategies is also cost-effective and would reduce pain related healthcare 
costs (Meissner et al., 2015).  Lastly, opioid-related side effects and adverse events would 
decrease through opioid-reduced multimodal management of postoperative pain 
(Helander et al., 2017).  
Limitations 
There were several limitations in this project.  First, this project used a self-
selected group that collected self-reported data, thus introducing bias into the results.  
Second, although a subanesthetic dose of 0.5-mg/kg was suggested, it is not known for 
certain that this dosage was used.  Third, the total number of patients eligible to receive 
subanesthetic ketamine during the two-week period is unknown.  As a result, it is 
 27 
impossible to know what percent of eligible patients received the intervention.  Fourth, 
data on the effect of subanesthetic ketamine on patient pain postoperatively was not 
assessed because the project was not able to follow patients through their first 24-hours 
postoperatively to determine the impact on eventual opioid use.  Finally, 2 weeks may be 
too short to assess sustainability of a practice change.  The long-term benefit of non-
opioid anesthesia for patients could not be assessed within the timeframe of this project.  
Thus, the efficiency and effectiveness of subanesthetic ketamine as part of a multimodal 
pain management regimen could not be established. 
Other circumstances limited the findings of this project.  A small sample size 
produced non-generalizable results with no reliability, minimal internal validity, and no 
external validity.  This project also had an insufficient time frame.  Patients with 
contraindications to ketamine administration may have limited the number of times 
participants could safely utilize the medication in such a short time period which could 
have effected results. 
Recommendations for Future Study 
Based on evidence cited in this project, the use of subanesthetic ketamine for 
postoperative analgesia can be anticipated to improve patient outcomes when part of a 
multimodal pain management plan.  Future studies should examine barriers to 
subanesthetic ketamine administration.  For example, some CRNAs cite the cost of a 
multi-dose vial and the necessity of wasting doses as barriers for adoption. Therefore, it 
would be important to understand what the impact of prefilled syringes would be on the 
decision to include ketamine in a multimodal pain management plan.  A study looking at 
ketamine usage before and after pharmacy provides single dose syringes would provide 
 28 
data for this potential barrier.  Future studies should examine the opioid-sparing effects of 
subanesthetic ketamine by measuring the amounts opioids patients receive 
postoperatively using morphine equivalents.  What procedure and patient specific 
attributes increase postoperative opioid consumption despite subanesthetic ketamine 
administration? 
Future studies should monitor patient outcomes over time.  The sixth and final 
step of the EBP model by Rosswurm and Larrabee involves integrating and maintaining a 
change in practice that includes subanesthetic ketamine as an adjunct in the multimodal 
management of acute postoperative pain (Rosswurm & Larrabee, 1999).  To sustain a 
change in practice patient outcomes must be periodically monitored 
Conclusion 
This project described pain management practices before and after an evidence-
based presentation on multimodal pain management using subanesthetic ketamine.  
Unmentioned until now, and relevant to this project, is the opioid crisis.  Opioid addiction 
and abuse is a public health problem that is now an epidemic of opioid overdoses and 
opioid related deaths (Rudd, 2016).  The problem is so widespread that many surgical 
patients are concerned with taking opioids preoperatively and post-discharge 
(Apfelbaum, Chen, Mehta, and Gan, 2003).  If given a choice, roughly 72% of surgical 
patients prefer a non-narcotic analgesic after surgery (Apfelbaum, Chen, Mehta, and Gan, 
2003).  Their reasoning was because non-narcotic medication are less addictive (49%) 
and have fewer side effects (18%) (Apfelbaum, Chen, Mehta, and Gan, 2003).  Over 
500,000 Americans have died from drug overdose from 2000 to 2015 and 91 people die 
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the same fate every day (Rudd, 2016).  Exploring opioid sparing multimodal approaches 
that utilize subanesthetic ketamine has national implications to public health. 
 Postoperative pain management is a challenging and pivotal component of 
anesthesia.  Despite their efficacy and place in anesthesia, opioids as mainstay analgesics 
have failed to provide patients with optimal postoperative pain control for more than a 
decade.  Unimodal opioid use increases postoperative risk for opioid related adverse 
events and can increase patient risk for becoming opioid dependent and long-term users 
(Brummett et al., 2017). 
 
 30 
APPENDIX A – DNP Essentials 
Table A1.  
The AACN Essentials of Doctoral Education for Advanced Nursing Practice 
Essential How the Essential was Achieved 
I.           Scientific Underpinnings 
for Practice 
This project described the pathophysiological 
effects of acute pain, explained the 
pharmacology of multimodal analgesia, and 
discussed the pharmacokinetics and 
pharmacodynamics of ketamine.  
Considering this information, strategies to 
translate research to practice were developed. 
II.          Organizational and 
Systems Leadership for 
Quality Improvement and 
Systems Thinking 
This project evaluated pain management 
regimens of CRNAs in a facility in the 
Southeastern U.S.  Strategies for effective 
perioperative pain management using 
subanesthetic ketamine as an adjunct in the 
multimodal management of acute 
postoperative pain were presented to improve 
quality of care. 
III.         Clinical Scholarship and 
Analytical Methods for 
Evidence-Based Practice 
This project appraised and disseminated the 
most current evidence on subanesthetic 
ketamine administration for acute 
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postoperative pain.  This evidence was 
presented to CRNAs and a evidence-based 
change in practice that included subanesthetic 
ketamine was proposed.   
V.         Health Care Policy for 
Advocacy in Health Care 
This project advocated for surgical patients 
by proposing an evidenced-based change in 
practice to improve the quality of pain 
management in this population and influence 
institutional leadership to support 
implementation of this evidenced-based 
practice change.  This project proposed an 
evidence-based practice change utilizing 
subanesthetic ketamine to improve the 
treatment of pain through the postoperative 
period. 
VII.       Clinical Prevention and 
Population Health for 
Improving the Nation’s 
Health 
To avert the opioid crisis in the U.S., this 
project asserted that effective pain 
management during the postoperative period 
decreases the risk for acute pain transitioning 
to chronic pain and the prolonged need 
and/or dependency on opioid. 
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VIII.     Advanced Nursing 
Practice 
This project proposed a practice change that 
includes the use of subanesthetic ketamine as 
an adjunct in the multimodal management of 
acute postoperative pain. 
 
Note: Chism, L. (2013). The doctor of nursing practice: A guidebook for role 
development and professional issues (2nd ed.). Burlington, MA: Jones & Bartlett 
Learning. 
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APPENDIX B – Review of Literature 
Table A2. Literature Matrix 
Author, Year, 
Title 
Level/
Grade 
Purpose Design Sample/ 
Data 
Collection 
Outcome, 
Recommendations 
Gao, M., 
Rejaei, D., & 
Liu, H. 
(2016). 
Ketamine use 
in current 
clinical 
practice.  
 
I Pharmacokinetics 
and 
pharmacodynamics 
of ketamine; 
clinical application 
of ketamine 
including risks and 
benefits 
Meta-
analysis 
Systematic 
review of 
literature 
Analgesic/Low dose 
range 0.25-1 mg/kg; 
evidence supports the 
use of ketamine for 
acute pain 
management in 
postoperative period. 
Preoperative dose of 
0.1mg/kg showed 
opioid sparing effect. 
For postoperative 
pain, low-dose 
reduced opioid 
requirements in first 
24 hours 
postoperatively and 
reduced postoperative 
nausea and vomiting. 
Jouguelet-
Lacoste, J., La 
Colla, L., 
Schilling, D., 
& Chelly, J. E. 
(2015). The 
Use of 
Intravenous 
Infusion or 
Single Dose of 
Low-Dose 
Ketamine for 
Postoperative 
Analgesia: A 
Review of the 
Current 
Literature. 
I Evaluate the 
efficacy of low-
dose ketamine in 
managing 
postoperative pain 
Systema
-tic 
Review 
Review of 
literature 
including 
all 
randomized 
controlled 
trials, 
meta-
analysis, 
and 
systematic 
reviews 
39 clinical trials 
assessed infusion and 
bolus of low dose 
ketamine. Low dose 
defined as < 1.2 
mg/kg. Mean 
reduction in opioid 
use in 40% of 
patients. Low-dose 
ketamine also result 
in lower pain scores 
and no major 
complications were 
found up to 48 hours 
postoperatively. 
Kaur, S., 
Saroa, R., & 
II Evaluate the effect 
of low-dose bolus 
Double 
blind 
80 patients 
undergoing 
Treatment group 
received preoperative 
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Aggarwal, S. 
(2015). Effect 
of 
intraoperative 
infusion of 
low-dose 
ketamine on 
management 
of 
postoperative 
analgesia.  
followed by 
intraoperative 
infusion on 
postoperative pain. 
random-
ized 
controll
-ed trial 
open 
cholecystec
-tomy 
bolus of 0.2 mg/kg 
and pre-incision 
infusion of 0.1 
mg/kg/h up to the end 
of surgery where it 
was discontinued. 
Effective analgesia 
for first six hours 
postoperatively. 
Laskowski, 
K., Stirling, 
A., McKay, 
W. P., & Lim, 
H. J. (2011). A 
systematic 
review of 
intravenous 
ketamine for 
postoperative 
analgesia.  
 
I Evaluate the 
efficacy of 
ketamine as 
adjunct in 
multimodal pain 
management plan.  
System-
atic 
Review 
Review of 
literature 
from 1966 
to 2010 
that 
included all 
randomized 
controlled 
trials, 
double-
blind, and 
placebo-
controlled, 
that 
utilized 
ketamine to 
decrease 
postoperati
-ve pain  
Ketamine effective 
adjunct in reducing 
postoperative pain. 
47 studies identified, 
reduction in total 
opioid consumption 
and an increase in 
time to first analgesic 
were observed in all 
studies (P<0.001). 
Greatest efficacy by 
surgical site 
identified as: 
thoracic, upper 
abdominal, major 
orthopedic 
procedures. When 
ketamine efficacious 
for pain, patients 
experienced less 
postoperative nausea 
and vomiting. 
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APPENDIX E – Pre-Intervention Questionnaire 
 
Data Collection Instrument: Pre-Intervention Questionnaire 
 
 
This questionnaire is intended to assess your current practice and typical approach to managing 
pain during the perioperative period.  Please complete each of the following questions.  When you are 
finished, place the questionnaire in the provided self-addressed envelope and mail to the principal 
investigator.   
Participation in this project is voluntary and not required.  Completion of this survey implies your 
consent to participate.  You may choose to withdraw from this project at any time.  
Thank you for your participation in this project. 
 
   
1. Gender: 
a. Male 
b. Female 
2. Age: _______years 
3. Years practice anesthesia: _______years 
4. Do you typically use a unimodal or multimodal pain management regimen? 
a. Unimodal 
b. Multimodal 
c. Don’t know 
d. Comments: 
__________________________________________________________________  
 
5. If you do use a multimodal regimen, rank the following adjuncts by how frequently you administer 
the drugs for their analgesic properties (rank from most frequent #1 to least frequent #) 
a. ____ Cyclooxygenase-2(COX-2) selective nonsteroidal anti-inflammatory drugs 
(NSAIDs)(COXIBs) 
b. ____ Nonselective NSAIDs 
c. ____ Calcium channel α-2-δ antagonists (gabapentin, pregabalin) 
d. ____ Ketamine 
e. ____ Acetaminophen 
 
6. Over the last two weeks, how many times have you administered subanesthetic ketamine for pain? 
a. 1-2 times 
b. 3-5 times 
c. None, I did not administer subanesthetic ketamine 
d. Don’t know 
 
7. Based on the evidence provided during this evidenced-based project, are you more likely to 
consider subanesthetic ketamine as an adjunct for perioperative pain control? 
a. Yes 
b. No 
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APPENDIX F – Post-Intervention Questionnaire 
 
Data Collection Instrument: Post-Intervention Questionnaire 
 
 
This questionnaire is intended to assess your current practice and typical approach to 
managing pain during the perioperative period.  Please complete each of the following questions.  
When you are finished, place the questionnaire in the provided self-addressed envelope and mail 
to the principal investigator.   
Participation in this project is voluntary and not required.  Completion of this survey 
implies your consent to participate.  You may choose to withdraw from this project at any time. 
Thank you for your participation in this project. 
 
 
1. Gender: 
a. Male 
b. Female 
2. Age: _______years 
3. Years practice anesthesia: _______years 
4. Do you typically use a unimodal or multimodal pain management regimen? 
a. Unimodal 
b. Multimodal 
c. Don’t know 
d. Comments: 
__________________________________________________________________  
 
5. If you do use a multimodal regimen, rank the following adjuncts by how frequently you 
administer the drugs for their analgesic properties (rank from most frequent #1 to least 
frequent #) 
a. ____ Cyclooxygenase-2(COX-2) selective nonsteroidal anti-inflammatory drugs 
(NSAIDs)(COXIBs) 
b. ____ Nonselective NSAIDs 
c. ____ Calcium channel α-2-δ antagonists (gabapentin, pregabalin) 
d. ____ Ketamine 
e. ____ Acetaminophen 
 
6. Over the last two weeks, how many times have you administered subanesthetic ketamine 
for pain? 
a. 1-2 times 
b. 3-5 times 
c. None, I did not administer subanesthetic ketamine 
d. Don’t know 
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APPENDIX G – Logic Model 
Table A3. Logic Model 
Resources Activities Outputs 
Short & Long 
Term Outcomes 
Impact 
• CRNA 
• Researcher 
• Time 
• Conduct a 
comprehen-
sive and 
systematic 
review of the 
literature 
• Present 
findings to 
CRNA 
• Discuss 
current pain 
management 
plan with 
CRNA 
 
• Summary 
of major 
findings 
to 
propose 
practice 
change 
• Conduct 
an 
evidenced
-based 
practice 
change 
proposal 
• Short term 
(1-3 years) 
improved 
management 
of 
postopera-
tive pain 
• Long term   
( 4-6 years) 
facility 
guideline on 
the use of 
multimodal 
pain 
management 
strategies 
that includes 
subanesthe-
tic ketamine 
• Multi-
modal a 
standard of 
care 
• Reduction 
in facility 
costs 
• Improved 
patient 
outcomes 
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